Released Aug 6, 2019, after the close
10-Q filed Aug 6, 2019, 37 days after period end · 0001232524-19-000044
Q2 2019 · 10-Q
Revenue$534.13M$534.13M +6.7% vs Q2 2018+5.1% vs Q1 2019
Net Income$261.90M$261.90M +183.7% vs Q2 2018+207.4% vs Q1 2019
EPS Diluted$4.56$4.56 +204.0% vs Q2 2018+210.2% vs Q1 2019
Gross Profit$495,747,000+7.4%
Operating Income$204,283,000+33.3%
Operating Cash Flowderived$148,847,000−22.5%
Free Cash Flowderived$134,884,000−28.2%
Margins · derived
Gross margin92.8%+0.6 pt vs Q2 2018
Operating margin38.2%+7.6 pt vs Q2 2018
Net margin49.0%+30.6 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $534.13M | $500.48M | $394.39M | $381.16M |
| Net Income | $261.90M | $92.32M | $105.60M | $114.50M |
| EPS Diluted | $4.56 | $1.50 | $1.72 | $1.85 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR